Patents by Inventor Anja Jäschke
Anja Jäschke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10828810Abstract: A method for the production of a vehicle body element is disclosed, wherein the vehicle body element is provided as a component composite comprised of at least one carrier profile part having a hollow structure, and a lightweight material, for example plastic. A liquid starting component of the lightweight construction material is introduced into the hollow structure of the carrier profile part and is then cured to forms the component composite.Type: GrantFiled: November 27, 2014Date of Patent: November 10, 2020Assignee: AUDI AGInventors: Anja Jäschke, Mario Boehme
-
Publication number: 20160318220Abstract: A method for the production of a vehicle body element is disclosed, wherein the vehicle body element is provided as a component composite comprised of at least one carrier profile part having a hollow structure, and a lightweight material, for example plastic. A liquid starting component of the lightweight construction material is introduced into the hollow structure of the carrier profile part and is then cured to forms the component composite.Type: ApplicationFiled: November 27, 2014Publication date: November 3, 2016Applicant: AUDI AGInventors: Anja JÄSCHKE, MARIO BOEHME
-
Patent number: 9394009Abstract: In a method for connecting at least two structural units for a body of a vehicle, which structural units have in each case at least one carrier unit which is in the form of a hollow profile and which has at least one reinforcement element arranged in the carrier unit, the respective reinforcement element is connected by structural foam to the corresponding carrier unit, wherein the reinforcement elements of the two structural units are formed in each case with a joining portion and are joined to one another. The structural units to be connected are aligned, and the reinforcement elements are pre-fixed in the carrier units before a heat treatment of the structural units, and are finally fixed by foaming and/or adhesive bonding after the heat treatment.Type: GrantFiled: March 23, 2013Date of Patent: July 19, 2016Assignee: AUDI AGInventor: Anja Jäschke
-
Publication number: 20150313881Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: April 29, 2015Publication date: November 5, 2015Inventors: ROGER J. DAVIS, ANJA JAESCHKE
-
Patent number: 9061009Abstract: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders.Type: GrantFiled: June 9, 2008Date of Patent: June 23, 2015Assignee: University of MassachusettsInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20150115640Abstract: In a method for connecting at least two structural units for a body of a vehicle, which structural units have in each case at least one carrier unit which is in the form of a hollow profile and which has at least one reinforcement element arranged in the carrier unit, the respective reinforcement element is connected by means of structural foam to the corresponding carrier unit, wherein the reinforcement elements of the two structural units are formed in each case with a joining portion and are joined to one another. The structural units to be connected are aligned, and the reinforcement elements are pre-fixed in the carrier units before a heat treatment of the structural units, and are finally fixed by foaming and/or adhesive bonding after the heat treatment.Type: ApplicationFiled: March 23, 2013Publication date: April 30, 2015Applicant: Audi AGInventor: Anja Jäschke
-
Publication number: 20140107123Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: August 5, 2013Publication date: April 17, 2014Applicant: University of MassachusettsInventors: Roger J. Davis, Anja Jaeschke
-
Patent number: 8501812Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: GrantFiled: March 1, 2011Date of Patent: August 6, 2013Assignee: University of MassachusettsInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20120208846Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: March 1, 2011Publication date: August 16, 2012Inventors: Roger J. Davis, Anja Jaeschke
-
Patent number: 7897572Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: GrantFiled: December 21, 2006Date of Patent: March 1, 2011Assignee: University Of Massachusetts Medical SchoolInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20100215665Abstract: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders.Type: ApplicationFiled: June 9, 2008Publication date: August 26, 2010Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Roger J. Davis, Anja Jaeschke
-
Publication number: 20060223807Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.Type: ApplicationFiled: March 29, 2005Publication date: October 5, 2006Applicant: University of Massachusetts Medical School, a Massachusetts corporationInventors: Roger Davis, Anja Jaeschke
-
Publication number: 20050004068Abstract: Methods for screening for potential modulators of mammalian target of rapamycin (mTOR) are provided based on detecting cellular ATP levels. Also provided are compositions useful in treating diseases or conditions dependent on mTOR signaling, including cancer, rheumatoid arthritis, restinosis and transplant rejection.Type: ApplicationFiled: October 11, 2002Publication date: January 6, 2005Inventors: Patrick Dennis, Anja Jaeschke, Sara Kozma, Masao Saitoh, George Thomas